| BackgroundHelicobacter pylori(H.pylori)is a kind of micro aerobic,spiral,Gram-negative bacteria.At present,the infection rate of Helicobacter pylori in China is about 58%.Helicobacter pylori infection is associated with a variety of gastrointestinal diseases.In recent years,due to the abuse of antibiotics,the emergence of antibiotic resistant strains of Helicobacter pylori,which reduces the effect of antibiotic treatment,has a serious impact on the treatment of Helicobacter pylori infection and the economic and quality of life of patients.Probiotics,as the auxiliary factors of normal nutrient absorption and intestinal immune function,has become the current research topic Focus.Objectiveto investigate the effect of probiotics in adjuvant treatment of drug resistant Helicobacter Pylori Gastritis,and to provide basis for clinical treatment of drug resistant Helicobacter Pylori.MethodFrom May 2018 to December 2019,163 patients were diagnosed as Helicobacter pylori chronic gastritis(non-atrophic gastritis)in the Department of gastroenterology of the988 th Hospital of the Joint Logistics Department.The results of Helicobacter Pylori were positive after traditional triple Helicobacter Pylori(Proton-pump inhibitor + antibiotics)treatment.All subjects were subjected to Helicobacter pylori susceptibility tests,and patients with drug resistant Helicobacter pylori strains were screened based on the results of the susceptibility tests.According to inclusion exclusion criteria,study subjects were selected and randomly divided into control group,probiotics Group A,probiotics group B.The patients in the control group were treated with conventional Helicobacter Pylori,the patients in the probiotics group a were treated with Bacillus subtilis enteric-coated capsule,and the patients in the probiotics group B were treated with blasé yeast powder.After taking probiotics,take antibiotics at least 3 hours apart.General clinical data such as age and sex of the patients were collected and 14 C Helicobacter Pylori was performed to calculate the eradication rate of Helicobacter Pylori.The clinical symptoms and adverse reactions of the patients were collected and scored.Meanwhile,the recurrence of the patients was followed up to evaluate the effect of probiotics on the treatment of drug resistant Helicobacter pylori gastritis.Result1.A total of 84 patients with resistant strains of Helicobacter Pylori were isolated from 163 patients,and the rate of Helicobacter pylori was 51.53%,the resistant rate of Clarithromycin was 32.56%,the resistant rate of Metronidazole was 11.66%,the resistant rate of Amoxicillin was 7.36%,the resistant rate of Levofloxacin was 1.84%,the resistant rate of tetracycline and Furazolidone was not isolated.Among the 84 drug-resistant strains,the single drug resistance rate was 67.86%,the double drug resistance rate was 25%,and the multiple drug resistance rate was 7.14%.2.After treatment,the eradication rate of control group was 57.14%,probiotics a group was 84.62%,probiotics B group was 88.89%,the difference was statistically significant(p < 0.05),the eradication rates of probiotics a group and probiotics B group were significantly increased(p < 0.05),and the Helicobacter Pylori eradication rates of Control Group,probiotics a group and probiotics B group were 57.14%,71.43% and78.57% respectively after 1 month of withdrawal,the eradication rate of probiotics a group and probiotics B group was significantly higher than that of Control Group(p < 0.05).3.The clinical symptom scores of Control Group and probiotics Group A and B were13.28 ± 0.34,13.21 ± 0.36 and 13.22 ± 0.53,respectively.After 7 days of treatment,the clinical symptoms were 8.29 ± 0.12,6.37 ± 0.27 and 6.22 ± 0.29,respectively,the clinical symptom scores were 5.87 ± 0.02,2.78 ± 0.03 and 2.88 ± 0.04 on the 14 th day after treatment,and were significantly lower than those before treatment(p < 0.05)on the 7thand 14 th day after treatment,the difference was statistically significant(p < 0.05).4.During the course of treatment,the incidence of adverse reaction was 17.86% in the control group,3.85% in the probiotics a group and 7.41% in the probiotics B group After half a year follow-up,12 cases(42.86%)recurred in the control group,4 cases(17.86%)in the probiotics a group and 3 cases(14.29%)in the probiotics B group.The recurrence rate in the control group was significantly higher than that in the probiotics group(p < 0.05).ConclusionProbiotics combined with Helicobacter Pylori therapy can improve the eradication rate of drug resistant Helicobacter Pylori patients,help patients with clinical symptoms and reduce adverse reactions. |
PDF Full Text Request